Gamma Scintigraphy of the Biodistribution of123I-Labelled N-(2-Hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates in Mice with Transplanted Melanoma and Mammary Carcinoma
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 3 (5) , 375-383
- https://doi.org/10.3109/10611869608996828
Abstract
An N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin conjugate is currently under clinical evaluation as a new antitumour agent. It has been shown previously that such conjugates exhibit selective tumour accumulation. In this study HPMA copolymer doxorubicin conjugates of low (LMW) or high (HMW) molecular weight were synthesised (which had a weight average molecular weight (Mw) of 25,000 and 94,000 respectively) and additionally contained a small amount (1 mol%) of the comonomer methacryloyltyrosinamide to permit labelling with [123I or 125I]iodide. Gamma camera imaging using the I-labelled probes was used to follow time-dependent biodistribution after intraperitoneal (i.p.) or intravenous (i.v.) administration to mice bearing subcutaneously either B16F10 melanoma or a mammary carcinoma. Imaging showed more rapid clearance of LMW conjugate from the peritoneal cavity than HMW conjugate. The images of mice given the LMW conjugate revealed rapid urinary excretion of radioactivity after both i.p. and i.v. injection with an early high concentration of tracer in the bladder, and subsequently a very high concentration in the kidneys, which came to dominate the views. Dissection analysis 2 days after administration of the LMW conjugate revealed a kidney level of radioactivity corresponding to 25-40 %dose/g tissue in mice bearing the two tumour models. Following administration of the HMW conjugate kidney accumulation at 2 days was less due to retention of the higher molecular weight polymer molecules in the circulation, and spleen and liver displayed the highest concentrations of radioactivity. The tumour accumulation of LMW and HMW conjugates was; mammary carcinoma 3.18 and 5.29 % dose/g respectively; B16F10 melanoma 3.23 and 8.82 %dose/g although these levels of tracer enabled visualisation in the images of the mammary carcinoma with HMW conjugate at later time points. The smaller size of the B16F10 tumour masses did not permit clear visualisation.Keywords
This publication has 17 references indexed in Scilit:
- Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrierEuropean Journal Of Cancer, 1995
- Polymeric Drug-Carriers Containing Doxorubicin and Melanocyte-Stimulating Hormone:In VitroandIn VivoEvaluation Against Murine MelanomaJournal of Drug Targeting, 1993
- Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivoBioconjugate Chemistry, 1992
- Drug-polymer conjugatesAnti-Cancer Drugs, 1992
- Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiographyCancer Immunology, Immunotherapy, 1991
- The pharmacokinetics of polymer-bound adriamycinBiochemical Pharmacology, 1990
- Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycinImmunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitroBiomaterials, 1989
- Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour modelBiochemical Pharmacology, 1989
- An improved Iodogen method of labelling antibodies with 123INuclear Medicine Communications, 1986
- Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers a potential drug delivery systemBiochimica et Biophysica Acta (BBA) - General Subjects, 1981